Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions.
NV trading halted, news pendingDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...
Benzinga Finance on MSN5d
Mainz Biomed $MYNZ & Thermo Fisher Partner On Next-Gen Colorectal Cancer Screening ProductMines Biomed, a molecular genetics diagnostic company, has entered into a collaborative agreement with Thermo Fisher ...
Mainz Biomed (MYNZ) announced a 1-for-40 reverse stock split of its issued and outstanding shares. The reverse stock split was authorized by ...
From clinical developments to an upcoming FDA trial anticipated in 2025, Mainz Biomed NV MYNZ, the molecular genetics diagnostic company, is making headway in growing its business on its path to ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Thermo Fisher Scientific has signed an agreement with German molecular genetics company Mainz Biomed, the developer of ColoAlert. “We are excited at the prospect of working with Mainz Biomed on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback